

## Freedom of Information Request: Our Reference CTMUHB\_58\_23

### You asked:

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

**Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Filgotinib**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Ozanimod**
- **Tofacitinib**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**

Please see provided below a table populated with the data that Medicines Management are able to provide in relation to your enquiry. The period relates to the last 3 months available which is 1<sup>st</sup> November 2022 to 31<sup>st</sup> January 2023.

<b>Medicine</b>	<b>Number of Patients</b>
Adalimumab - Humira	7
Adalimumab Biosimilar	160
Filgotinib	0
Golimumab	0
Infliximab - Remicade	**
Infliximab Biosimilar	159
Ozanimod	0
Tofacitinib	**
Upadacitinib	0
Ustekinumab	112
Vedolizumab	156

Where the figures are less than 5, this has been denoted by \*\*. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful

processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

**Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs:**

- **Adalimumab - Humira**
- **Adalimumab Biosimilar**
- **Golimumab**
- **Infliximab - Remicade**
- **Infliximab Biosimilar**
- **Upadacitinib**
- **Ustekinumab**
- **Vedolizumab**

Unfortunately, we are unable to provide a response to question 2 because our electronic dispensing system does not record the condition being treated.

The information you require would be recorded within an individual patient's health record as part of their ongoing care. To provide you with this information, would require a manual trawl and significantly exceed the 18 hours time and £450 cost limit set out within Section 12 of the Freedom of Information Act.